9 June 2021 - Secura Bio today announced that on 19 May 2021, the European Medicines Agency granted marketing authorisation for Copiktra as monotherapy for the treatment of relapsed or refractory chronic lymphocytic leukaemia in patients, who have received at least two prior therapies and for the treatment of follicular lymphoma that is refractory to at least two prior systemic therapies.

Copiktra is a dual inhibitor of PI3K delta and gamma pathways, which are involved in the proliferation of malignant cells and are thought to play a role in the formation and maintenance of the supportive tumour microenvironment.

Read Secura Bio press release